LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons.

    Levi, Nir / Moravsky, Gil / Weitsman, Tatyana / Amsalem, Itshak / Bar-Sheshet Itach, Sarit / Algur, Nurit / Lapidus, Ira / Mitz, Ofir / Glikson, Michael / Wiener-Well, Yonit / Hasin, Tal

    European journal of heart failure

    2022  Volume 25, Issue 2, Page(s) 313–318

    Abstract: Aims: To prospectively evaluate the incidence of myocardial injury after the administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19.: Methods and results: Health care workers who received the BNT162b2 vaccine ... ...

    Abstract Aims: To prospectively evaluate the incidence of myocardial injury after the administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19.
    Methods and results: Health care workers who received the BNT162b2 vaccine during the fourth dose campaign had blood samples collected for high-sensitivity cardiac troponin (hs-cTn) during vaccine administration and 2-4 days afterward. Vaccine-related myocardial injury was defined as hs-cTn elevation above the 99th percentile upper reference limit and >50% increase from baseline measurement. Participants with evidence of myocardial injury underwent assessment for possible myocarditis. Of 324 participants, 192 (59.2%) were female and the mean age was 51.8 ± 15.0 years. Twenty-one (6.5%) participants had prior COVID-19 infection, the mean number of prior vaccine doses was 2.9 ± 0.4, and the median time from the last dose was 147 (142-157) days. Reported vaccine-related adverse reactions included local pain at injection site in 57 (17.59%), fatigue in 39 (12.04%), myalgia in 32 (9.88%), sore throat in 21 (6.48%), headache in 18 (5.5%), fever ≥38°C in 16 (4.94%), chest pain in 12 (3.7%), palpitations in 7 (2.16%), and shortness of breath in one (0.3%) participant. Vaccine-related myocardial injury was demonstrated in two (0.62%) participants, one had mild symptoms and one was asymptomatic; both had a normal electrocardiogram and echocardiography.
    Conclusion: In a prospective investigation, an increase in serum troponin levels was documented among 0.62% of healthy health care workers receiving the fourth dose BNT162b2 vaccine. The two cases had mild or no symptoms and no clinical sequela.
    Clinical trial registration: ClinicalTrials.gov Identifier: NCT05308680.
    MeSH term(s) Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; BNT162 Vaccine ; COVID-19/prevention & control ; Heart Failure ; Prospective Studies ; Vaccination ; COVID-19 Vaccines/adverse effects
    Chemical Substances BNT162 Vaccine ; COVID-19 Vaccines
    Language English
    Publishing date 2022-09-28
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1483672-5
    ISSN 1879-0844 ; 1388-9842
    ISSN (online) 1879-0844
    ISSN 1388-9842
    DOI 10.1002/ejhf.2687
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5299: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Effect of Acetazolamide on Obesity-Induced Glomerular Hyperfiltration: A Randomized Controlled Trial.

    Zingerman, Boris / Herman-Edelstein, Michal / Erman, Arie / Bar Sheshet Itach, Sarit / Ori, Yaacov / Rozen-Zvi, Benaya / Gafter, Uzi / Chagnac, Avry

    PloS one

    2015  Volume 10, Issue 9, Page(s) e0137163

    Abstract: Aims: Obesity is an important risk factor for the development of chronic kidney disease. One of the major factors involved in the pathogenesis of obesity-associated kidney disease is glomerular hyperfiltration. Increasing salt-delivery to the macula ... ...

    Abstract Aims: Obesity is an important risk factor for the development of chronic kidney disease. One of the major factors involved in the pathogenesis of obesity-associated kidney disease is glomerular hyperfiltration. Increasing salt-delivery to the macula densa is expected to decrease glomerular filtration rate (GFR) by activating tubuloglomerular feedback. Acetazolamide, a carbonic anhydrase inhibitor which inhibits salt reabsorption in the proximal tubule, increases distal salt delivery. Its effects on obesity-related glomerular hyperfiltration have not previously been studied. The aim of this investigation was to evaluate whether administration of acetazolamide to obese non diabetic subjects reduces glomerular hyperfiltration.
    Materials and methods: The study was performed using a randomized double-blind crossover design. Obese non-diabetic men with glomerular hyperfiltration were randomized to receive intravenously either acetazolamide or furosemide at equipotent doses. Twelve subjects received the allocated medications. Two weeks later, the same subjects received the drug which they had not received during the first study. Inulin clearance, p-aminohippuric acid clearance and fractional lithium excretion were measured before and after medications administration. The primary end point was a decrease in GFR, measured as inulin clearance.
    Results: GFR decreased by 21% following acetazolamide and did not decrease following furosemide. Renal vascular resistance increased by 12% following acetazolamide, while it remained unchanged following furosemide administration. Natriuresis increased similarly following acetazolamide and furosemide administration. Sodium balance was similar in both groups.
    Conclusions: Intravenous acetazolamide decreased GFR in obese non-diabetic men with glomerular hyperfiltration. Furosemide, administered at equipotent dose, did not affect GFR, suggesting that acetazolamide reduced glomerular hyperfiltration by activating tubuloglomerular feedback.
    Trial registration: ClinicalTrials.gov NCT01146288.
    MeSH term(s) Acetazolamide/pharmacology ; Acetazolamide/therapeutic use ; Adult ; Carbonic Anhydrase Inhibitors/pharmacology ; Carbonic Anhydrase Inhibitors/therapeutic use ; Diuretics/pharmacology ; Furosemide/pharmacology ; Glomerular Filtration Rate ; Humans ; Kidney Diseases/drug therapy ; Kidney Diseases/etiology ; Male ; Middle Aged ; Obesity/complications
    Chemical Substances Carbonic Anhydrase Inhibitors ; Diuretics ; Furosemide (7LXU5N7ZO5) ; Acetazolamide (O3FX965V0I)
    Language English
    Publishing date 2015
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0137163
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article: Acetylcholinesterase-R increases germ cell apoptosis but enhances sperm motility.

    Mor, I / Sklan, E H / Podoly, E / Pick, M / Kirschner, M / Yogev, L / Bar-Sheshet Itach, S / Schreiber, L / Geyer, B / Mor, T / Grisaru, D / Soreq, H

    Journal of cellular and molecular medicine

    2008  Volume 12, Issue 2, Page(s) 479–495

    Abstract: Changes in protein subdomains through alternative splicing often modify protein-protein interactions, altering biological processes. A relevant example is that of the stress-induced up-regulation of the acetylcholinesterase (AChE-R) splice variant, a ... ...

    Abstract Changes in protein subdomains through alternative splicing often modify protein-protein interactions, altering biological processes. A relevant example is that of the stress-induced up-regulation of the acetylcholinesterase (AChE-R) splice variant, a common response in various tissues. In germ cells of male transgenic TgR mice, AChE-R excess associates with reduced sperm differentiation and sperm counts. To explore the mechanism(s) by which AChE-R up-regulation affects spermatogenesis, we identified AChE-R's protein partners through a yeast two-hybrid screen. In meiotic spermatocytes from TgR mice, we detected AChE-R interaction with the scaffold protein RACK1 and elevated apoptosis. This correlated with reduced scavenging by RACK1 of the pro-apoptotic TAp73, an outcome compatible with the increased apoptosis. In contrast, at later stages in sperm development, AChE-R's interaction with the glycolytic enzyme enolase-alpha elevates enolase activity. In transfected cells, enforced AChE-R excess increased glucose uptake and adenosine tri-phosphate (ATP) levels. Correspondingly, TgR sperm cells display elevated ATP levels, mitochondrial hyperactivity and increased motility. In human donors' sperm, we found direct association of sperm motility with AChE-R expression. Interchanging interactions with RACK1 and enolase-alpha may hence enable AChE-R to affect both sperm differentiation and function by participating in independent cellular pathways.
    MeSH term(s) Acetylcholinesterase/genetics ; Acetylcholinesterase/metabolism ; Alternative Splicing ; Animals ; Apoptosis/genetics ; Biopsy ; Humans ; Immunohistochemistry ; Male ; Mice ; Mice, Transgenic ; Models, Biological ; Sperm Motility/genetics ; Spermatozoa/cytology ; Spermatozoa/enzymology ; Spermatozoa/physiology ; Testis/cytology ; Testis/enzymology ; Testis/metabolism ; Testis/physiology ; Testis/surgery
    Chemical Substances Acetylcholinesterase (EC 3.1.1.7)
    Language English
    Publishing date 2008-04
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2074559-X
    ISSN 1582-4934 ; 1582-1838 ; 1582-4934
    ISSN (online) 1582-4934
    ISSN 1582-1838 ; 1582-4934
    DOI 10.1111/j.1582-4934.2008.00231.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5752: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top